• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

The Adoption of Prescription Digital Therapeutics and Its Challenges Amongst Payers | Asembia Specialty Pharmacy Summit

Video

Today at the annual Asembia Specialty Summit in Las Vegas, Sarah Marche, VP of Pharmacy at Highmark Health, spoke alongside other professionals from various stakeholders within the industry who are invested some way in digital therapeutics.

Prescription digital therapeutics are increasingly becoming an important part of how we manage diseases, said Sarah Marche, VP of Pharmacy at Highmark Health, in the interview above with Managed Healthcare Executive.

"I'd say more and more patients are turning to apps and their phones to supplement how they're treating certain disease states," she added.

Today at the annual Asembia Specialty Summit in Las Vegas, Marche spoke alongside other professionals from various stakeholders within the industry who are invested some way in digital therapeutics.

Marche dove into her discussion focusing on payer's perspectives on the coverage of precription digital therapeutics.

"There are some issues we see with (prescription digital therapeutics)," Marche said. "I run the pharmacy benefit for Highmark and we're used to very robust and structured clinical data and studies. The studies that we see around digital therapeutics are not similar to what we're used to seeing."

To hear more about her discussion, watch the interview above with Marche above.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.